Peanut allergy immunotherapy - DBV Technologies

Drug Profile

Peanut allergy immunotherapy - DBV Technologies

Alternative Names: DBV 712; EPIT® Peanut; Viaskin Peanut

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator DBV Technologies
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 03 Mar 2017 Pharmacodynamics data from studies in animal models presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 03 Mar 2017 Updated adverse events, efficacy data and immunogenicity data from the phase-IIb VIPES trial in Peanut hypersensitivity presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 07 Feb 2017 DBV Technologies initiates the follow-up phase III PEOPLE trial for Peanut hypersensitivity (In children) in USA, Canada, Ireland, Germany and Australia (Topical) (NCT03013517)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top